Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

The three top trends we saw in diabetes in 2013.
On March 3, AstraZeneca announced FDA approval for the Bydureon dual-chambered pen (once-weekly exenatide) to improve glycemic control in people with type 2. The device...
The Food and Drug Administration (FDA) on March 29, 2013 announced its approval of Janssen Pharmaceuticals' Invokana (canagliflozin), a new SGLT-2 inhibitor for type 2...
We ask ACA expert Dr. Jack Lord all the hard questions on healthcare coverage and reimbursement.
We travel to Oregon to support test strip access for people with diabetes. Find out what transpired!
Cellnovo recently launched its mobile-enabled insulin pump system in the UK, after receiving very positive feedback from a usability study that began in the UK in...
On March 25, Lilly and Boehringer Ingelheim (BI) announced that they submitted an application to the FDA for empagliflozin, an SGLT-2 inhibitor, for type 2 diabetes...
Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) released its safety review of incretin-based therapies for diabetes. It...
On January 8, the FDA approved Farxiga (dapaglifozin) for the treatment of type 2 diabetes. The drug is called Forxiga in Europe, where it has been approved since...
Do you ever wonder why there aren’t cheaper “generic” insulin products available? This may soon change as the patents for branded insulin begin to expire. In fact, the...
On April 16, Vivus announced that the FDA approved a change to the distribution of Qsymia . Qsymia is a weight loss and weight management drug that is designed to be...
Last month, in early September, results from the DPP-4 inhibitor cardiovascular outcomes trials SAVOR-TIMI 53 (for Bristol Myers Squibb and AstraZeneca’s Onglyza) and...
On November 22, J&J/Janssen Cilags’ SGLT-2 inhibitor Invokana (canagliflozin) was approved in Europe. This makes Invokana the second SGLT-2 inhibitor approved in...
On February 11, the FDA released a Drug Safety Communication requesting data from the widely publicized cardiovascular outcomes trial for Onglyza (saxagliptin). The...
What it felt like to forget about diabetes for a week.
On September 12, Sanofi announced that it withdrew the FDA application for its once-daily GLP-1 agonist lixisenatide (named Lyxumia in Europe) for type 2 diabetes. It is...
On November 25, the FDA announced the removal of the major restrictions on the prescription and use of GlaxoSmithKline’s Avandia (rosiglitazone) for type 2 diabetes...
The consensus from most speakers at the workshop was that, while this possible link does require further investigation, the available evidence does not suggest any need...
On Tuesday October 15, JDRF and PureTech announced the launch of T1D Innovations, an exciting new fund that aims to supply crucial funding for the development of type 1...

Pages